Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Relapsed/Refractory Breast, Colorectal, and NSCLC
NCT00126451Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2004
- Primary completion
- Oct 2005
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in breast cancer, colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), sponsored by Merck & Co. Primary endpoint: Response rate of relapsed/refractory breast, colorectal and non-small cell lung cancer to SAHA using RECIST criteria. Started Dec 2004; status: terminated.
02
Drugs
vorinostat
03
Conditions
breast cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00126451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126451.